Valuation: Royalty Pharma plc

Market Cap 26.08B 22.93B 21.34B 19.6B 36.8B 2,501B 37.29B 254B 99.07B 1,235B 97.89B 95.78B 4,268B P/E 2026 *
22.2x
P/E 2027 * 15.5x
Enterprise Value 35.23B 30.97B 28.83B 26.48B 49.72B 3,379B 50.37B 343B 134B 1,668B 132B 129B 5,766B EV / Sales 2026 *
10.2x
EV / Sales 2027 * 9.55x
Free-Float
71.97%
Yield 2026 *
1.7%
Yield 2027 * 1.79%
1 day-0.17%
1 week+2.50%
Current month+4.74%
1 month+2.87%
3 months+18.29%
6 months+44.16%
Current year+51.99%
1 week 56.9
Extreme 56.9
59.72
1 month 54.95
Extreme 54.95
59.72
Current year 38.29
Extreme 38.29
59.72
1 year 34.08
Extreme 34.0805
59.72
3 years 24.05
Extreme 24.05
59.72
5 years 24.05
Extreme 24.05
59.72
10 years 24.05
Extreme 24.05
59.72
Manager TitleAgeSince
Chief Executive Officer 62 1995-12-31
Director of Finance/CFO 44 2009-12-31
Chief Tech/Sci/R&D Officer - 2023-09-20
Director TitleAgeSince
Chairman 62 2020-03-31
Director/Board Member 68 2020-02-10
Director/Board Member 63 2020-06-15
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Executive/Senior Manager

-9,099 0.0021%
6/30/26 Free

Director

689 0.0002%
6/30/26 Sell

Executive/Senior Manager

-130,000 0.0293%
Change 5-day change 1-year change 3-year change Capi.($)
-0.17%+2.50%+58.47%+89.45% 26.08B
+0.13%+4.41%+48.19%+163.20% 1,067B
+0.97%+6.88%+60.00%+53.12% 635B
-0.94%+1.39%+36.28%+72.60% 458B
+1.41%+7.75%+38.93%+32.88% 347B
+1.28%+2.82%+38.42%+43.21% 295B
+1.72%+2.33%+19.31%+20.79% 262B
+1.84%-1.03%-27.78%-38.45% 216B
+0.06%+3.32%+24.88%+59.40% 203B
+0.94%-2.02%+15.47%+70.59% 161B
Average +1.12%+1.31%+31.22%+56.68% 366.96B
Weighted average by Cap. +0.97%+1.95%+37.90%+78.51%

Financials

2026 *2027 *
Net sales 3.47B 3.05B 2.84B 2.61B 4.9B 333B 4.96B 33.75B 13.18B 164B 13.02B 12.74B 568B 3.71B 3.26B 3.03B 2.79B 5.23B 355B 5.3B 36.05B 14.08B 175B 13.91B 13.61B 607B
Net income 1.65B 1.45B 1.35B 1.24B 2.33B 159B 2.36B 16.09B 6.28B 78.32B 6.21B 6.07B 271B 2.24B 1.97B 1.83B 1.68B 3.16B 215B 3.2B 21.76B 8.5B 106B 8.4B 8.22B 366B
Net Debt 9.15B 8.05B 7.49B 6.88B 12.92B 878B 13.09B 89.04B 34.77B 433B 34.36B 33.62B 1,498B 9.33B 8.2B 7.63B 7.01B 13.16B 894B 13.33B 90.71B 35.43B 442B 35.01B 34.25B 1,526B
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Employees
100
Date Price Change Volume
26-07-27 US$58.73 -0.17% 1,524,098
26-07-24 US$58.83 -0.32% 2,114,330
26-07-23 US$59.02 +0.51% 2,159,891
26-07-22 US$58.72 +0.51% 2,618,886
26-07-21 US$58.42 +1.96% 3,716,803
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
58.83USD
Average target price
59.89USD
Spread / Average Target
+1.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RPRX Stock